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Abstract
Background: China’s Ministry of Health (MOH) has established a policy about the antimicrobial stewardship. To
date, the effects of this policy on multidrug-resistant organism (MDRO) in critically ill patients are unknown.
Methods: A pre-post study was conducted on intensive care unit (ICU) patients from June 2010 to May 2011 and
from June 2012 to May 2013. Bacterial cultures were conducted at ICU admission and discharge. In June 2011, our
hospital started to administer the antimicrobial stewardship program of Chinese MOH. We collected the data on
antimicrobial consumption during the 3-year period in all hospital and individual department every month, and
analyzed the correlation between the proportion of critically patients colonized or infected with MDRO and
antimicrobial consumption.
Results: A total of 978 patients were involved in the present study. With the intervention, the monthly mean
Defined Daily Dose (DDD) per 100 occupied bed-days throughout the hospital decreased from 96 ± 7 to 65 ± 6
(p < 0.001), and the proportion of patients colonized or infected with MDRO decreased from 36 to 13% at the time
of ICU admission and declined from 48 to 29% at the time of ICU discharge (both p < 0.001). There was a significant
positive relationship between the proportion of all critically ill patients colonized or infected with MDRO at ICU
admission and the DDD of the entire hospital (R2 = 0.7858, p < 0.001).
Conclusion: The antimicrobial stewardship program of Chinese MOH reduced the consumption of antibiotics.
Moreover, the proportion of patients colonized or infected with MDRO decreased along with reduced consumption
of antibiotics.
Trial registration: Retrospectively registered: NCT02128399; Date of registration: 22 APR 2014; Detail information web
link: https://clinicaltrials.gov/ct2/show/NCT02128399?term=NCT02128399&rank=1
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Background
Antimicrobial exposure increases the selection for various
drug-resistant organisms [1]. Numerous studies have dem-
onstrated the association between antimicrobial use and
MDRO detection [2–4]. However, to our knowledge, there
are few data to support the concept that reducing antibiotic
use actually leads to improvements in antibiotic susceptibil-
ities [1]. Moreover, antimicrobial stewardship was demon-
strated to reduce MDRO and was strongly recommended
in clinics [5]. The World Health Organization (WHO)
strongly recommends that governments implement anti-
microbial stewardship programs directed at containing
antimicrobial resistance [6]. However, a considerable gap
exists between theory and clinical practice [7]. Antibiotic
use is increasing even in some countries such as Norwegian
with a low antibiotic resistance rate [8, 9].
In China, the overuse of antibiotics is common [10],
and the prevalence of antimicrobial resistance isolates is
higher than that in North America and Europe [11].
Data reported by the Chinese Ministry of Health (MOH)
National Antimicrobial Resistance Investigation Net
(Mohnarin) indicates that antimicrobial resistance is ris-
ing steadily [12]. In 2011, Chinese MOH established pol-
icies concerning the antimicrobial stewardship to
improve the intelligent use of antibiotics. Most hospitals
in China gradually implemented the policies. These pol-
icies included restricting the kinds of antibiotics, setting
the targets for antibiotic prescription in hospitalized pa-
tient and prophylactic use of antibiotics in clean opera-
tions (Please see the detail of polices in methods of
Antimicrobial stewardship). However, to the best of our
knowledge, no studies have shown whether the anti-
microbial stewardship can reduce infection or
colonization with MDRO in critically ill patients. There-
fore, in the present study, we aimed to elucidate the role
of the antimicrobial stewardship on the antimicrobial
consumption and infection or colonization with MDRO
in critically ill patients.
Methods
Study design
The pre-post study was performed in the ICU of a
university-affiliated hospital. The protocol was approved
by Nanjing Zhongda Hospital Institutional Ethics Com-
mittee (Approval Number: 2011ZDLL012.0). Written in-
formed consent was obtained from the patients or next
of kin. The trial was registered at clinicaltrials.gov
(NCT02128399).
The study was divided into two periods according to
the intervention of antibiotics management policy, which
started in June 2011. Phase 1 was defined as one year be-
fore the intervention (from June 2010 to May 2011).
Phase 2 was defined as one year after the intervention
(from June 2012 to May 2013). During the two phases of
the study, all patients hospitalized in the ICU and pa-
tients discharged from ICU before the end of the two
studied phases were eligible to participate in the study.
We only selected the data of patients for their first ad-
mission to ICU. Screening for MDRO was performed in
our ICU as part of an infection control policy, and
microbiological cultures of different specimens were per-
formed according to clinical status. Bacterial cultures
from nasal swabs, lower respiratory tract secretions and
the infected area were performed at the time of ICU ad-
mission and discharge.
We performed the same policy of screen during the
two study periods. We also had taken executive infection
control measures during this pre-post study period in
our hospital. All of the patients were treated by the at-
tending physician.
Antimicrobial stewardship
According to the protocol of antibiotic administrative
group, our hospital was directed to implement the proto-
col in June 2011. The policy included antibiotic procure-
ment was restricted to 50 agents in our hospital from June
2011. Meanwhile, targets for antibiotic prescription are set
at less than 60 and 20% of all prescriptions for hospitalized
patients and outpatients, respectively. Prophylactic use of
antibiotics in clean operations should be lowered to 30%
of patients and reduced to less than 24 h’ duration; and
antibiotic utilization in hospitalized patients should be less
than 40 Defined Daily Dose (DDD) per 100 patient; ra-
tionality of antibiotic use, which includes timing, duration
and appropriate medications should be more than 90%. In
our hospital, special antimicrobial agents, such as carba-
penem, glycopeptide, linezolid, daptomycin, and tigecyc-
line, must be approved by a designated doctor of
pharmacy; in particular case, such as during salvage, doc-
tors are permitted to urgently use these special antimicro-
bial no more than one day. The trained pharmacists and
infection preventionists were all part of the antimicrobial
stewardship in our hospital. They were responsible for
monitoring these medications, and every month, they an-
nounced the antimicrobial agents in every clinic and de-
partment. If the individual department did not reach the
targets which mentioned, the director of the department
would provide the reason and be warned by the hospital.
If there was no desirable reason why they could not
achieve the targets, the salary of all the staff of the depart-
ment would be deducted. During the study period, we
practiced infection control measures according to the rec-
ommendations of the Centers for Disease Control (CDC)
of the USA [13].
Data collection and definitions
Beginning in June 2011, the management of antibacterial
drugs in clinical applications was implemented in every
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department in our hospital. For each month, we re-
corded the aggregate data on active surveillance testing
and antibiotic consumption. We prospectively collected
all data concerning patient characteristics at the time of
ICU admission and during the patients’ ICU stay. We
collected information about ICU patients’ microbio-
logical culture results and antibiotic consumption
between June 2010 and the end of May 2011. The anti-
biotic consumption data were obtained from the hospital
computer center database.
We used the Defined Daily Dose DDD per 100 occu-
pied bed-days to indicate antibiotic consumption in our
hospital and every department. The DDD for adults was
obtained from the anatomical therapeutic chemical
(ATC) classification index from the WHO, with the
DDD unit expressed in grams.
MDRO were defined as bacteria were resistant to at
least three antimicrobial classes which included
methicillin-resistant Staphylococcus aureus (MRSA),
vancomycin-resistant enterococci (VRE), Pseudomonas
aeruginosa, Acinetobacter baumannii, and extended-
spectrum β-lactamase (ESBL)-producing or carbapenemase-
producing gram-negative bacilli [14]. We use laboratory
tests to determine these MDRO. Minimal Inhibitory Con-
centration (MIC) method was used to determine the bacter-
ial drug resistance. MRSA was defined as Staphylococcus
aureus resistant to oxacillin and VRE was defined as entero-
cocci resistant to vancomycin. ESBL-producing organisms
were defined as Gram-negative bacilli resistant to ceftazi-
dime but sensitive to enzyme inhibitor such as piperacillin–
tazobactam.
Statistical analysis
All of the statistical analyses were conducted using SPSS
13.0 software (release 13.0, SPSS, Chicago, IL, USA).
The distribution of quantitative variables was tested.
Normally and abnormally distributed quantitative
variables are presented as the mean ± standard deviation
and the median (25th–75th interquartile range), respect-
ively. All p values were two-tailed. A p < 0.05 was con-
sidered to be statistically significant.
We assessed the differences in categorical variables
using the χ2 test or Fisher’s exact test. We analyzed the
differences in length of ICU stay and stay until hospital
discharge or death using the Mann–Whitney U test.
Antibiotic consumption and infection or colonization
with MDRO were assumed to be independent variables;
the association between the 2 variables was evaluated




A total of 978 patients were involved in our study,
among whom 433 patients were involved before the
intervention and 545 patients were involved after the
antibacterial drug clinical application management. The
patient characteristics are presented in Table 1. Of the
978 patients, the median length of the ICU stay was 5
(2–10) days, and the median length of the hospital stay
was 18 (8–30) days. One hundred fifty-six (24%) patients
died in the ICU, and the hospital mortality rate was 26%
(Table 1). There were no significant differences in ICU
mortality, hospital mortality and length of ICU stay be-
tween both phases; however, the length of the hospital
stay was reduced after the intervention (17 days vs.
18 days, p = 0.009).
Antimicrobial consumption
The monthly antimicrobial consumption throughout the
hospital from June 2010 to May 2013 is shown in Fig. 1.
With the antimicrobial stewardship program in clinical
applications, we found that the rational use of antibiotics
had improved. In the preventative use of antibiotics in
Table 1 Summary of patient characteristics
All patients (978) Before management (433) After Management (545) p value
Age, years 64 ± 19 64 ± 19 65 ± 18 0.319
Male (%) 630 (64) 267 (62) 363 (67) 0.109
APACHEII score 16 ± 9 16 ± 9 16 ± 9 0.578
Admission source
Emergency 313 (32) 132 (30) 181 (33) 0.268
Surgery 473 (48) 205 (47) 268 (49) 0.569
Medicine 192 (20) 96 (22) 96 (18) 0.075
ICU mortality (%) 244 (25) 112 (26) 132 (24) 0.55
Hospital mortality (%) 281 (29) 133 (31) 148 (27) 0.22
Duration of ICU stay 5 (2–10) 5 (2–10) 5 (2–10) 0.954
Duration of hospitalization 17 (8–30) 18 (8–33) 17 (9–30) 0.009
APACHEII Acute Physiology and Chronic Health Evaluation II
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clean operation, for example, the percentage decreased
from nearly 100 to 35%. The DDD per 100 occupied bed-
days in our hospital decreased from 96 before intervention
to 65 after intervention (Table 2). In most departments,
the DDD per 100 occupied bed-days decreased similarly,
and only in the thoracic surgery, neurology and urology
departments, the DDD per 100 occupied bed-days did not
decrease from 2010 to 2013 (Table 2).
The monthly antimicrobial consumption in the ICU is
shown in Fig. 1. The DDD per 100 occupied bed-days in
the ICU during the study period was higher than that
observed in other departments. With the antimicrobial
stewardship, the DDD per 100 occupied bed-days also
decreased from 170 ± 28 to 159 ± 44 in ICU (p = 0.018).
During the antimicrobial stewardship, the category of
antibiotics did not change (Additional file 1: Table S1).
The median duration of antibiotics were 3.64 (1.96, 6.18)
and 3.42 (1.65, 6.19) before and after antimicrobial stew-
ardship, respectively. In addition, the dose of antibiotics
also did not change during the intervention.
Relevance ratio of multidrug-resistant organisms
The proportion of colonization and infection with MDRO
in critically ill patients at the time of ICU admission and
ICU discharge every month is shown in Fig. 2. Among the
total patients included in the study, the proportion of
MDRO isolates decreased from 36 to 13% at the time of
ICU admission and declined from 48 to 29% at the time
of ICU discharge (both p < 0.001). Proportion of MDRO
isolates of patients who admitted into ICU directly from
emergency department, which indicate that patients dir-
ectly colonized from the community, decreased from 40
to 18% (p < 0.001). Proportion of MDRO isolates of pa-
tients who transferred into ICU form other wards de-
crease from 34 to 11% (p < 0.001). However, the
proportion of MDRO isolates in patients from different
departments decreased in varying degrees, even in some
departments in which DDD was not decreased, such as in
the thoracic surgery department (Table 3).
There were 802 and 992 samples for culture in phase 1
and phase 2 at ICU admission, respectively. Table 4 dis-
plays the microorganisms associated with colonization or
infection at the time of ICU admission and ICU discharge.
Among the 273 MDRO present at the time of ICU admis-
sion, 75 (27.4%) were MRSA and 83 (30.4%) were A.
baumannii, which is the highest rate among Gram-
positive and Gram-negative bacterium, respectively. When
patients were discharged from the ICU, the rate of MRSA
decreased from 27.4 to 20.4%; however, A. baumannii in-
fection increased from 30.4 to 40.7%, whereas other bac-
terium did not change significantly (Table 4).
Correlation between antimicrobial consumption and
multidrug-resistant organisms
As the antibiotic consumption decreased after antibac-
terial drug clinical application management, the propor-
tion of colonization and infection with MDRO at the
time of ICU admission correspondingly decreased. The
Fig. 1 Antibiotic consumption of our hospital and ICU decreased after the management of antibacterial drugs in clinical applications
Table 2 Mean monthly DDD per 100 occupied bed-days before






All 96 ± 7 65 ± 6 <0.001
Neurosurgery 78 ± 26 45 ± 17 0.002
Thoracic surgery 96 ± 20 106 ± 36 0.38
General surgery 115 ± 16 93 + 20 0.003
Urology surgery 117 ± 15 129 ± 10 0.02
Orthopedics 82 ± 9 40 + 7 <0.001
Respiratory medicine 178 ± 18 128 + 15 <0.001
Neurology 36 ± 9 35 ± 12 0.963
Cardiology 74 ± 12 35 ± 6 <0.001
ICU 170 ± 28 159 ± 44 0.018
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total consumption of antibacterial agents each month
during the study period had a significant positive rela-
tionship with colonization and infection with MDRO in
critically ill patients at the time of ICU admission each
month (R2 = 0.7858, p < 0.001) (Fig. 3).
The DDD in the ICU may affect the MDRO propor-
tion of critically ill patients at the time of ICU discharge.
Therefore, we analyzed the relationship between these
two factors. Although the MDRO rate decreased after
the intervention, there was no significant relationship
between the MDRO isolates and the DDD in the ICU
(R2 = 0.1085, p = 0.116) (Fig. 4a). However, there was sig-
nificant relationship between an increased MDRO rate
from admission to discharge and the DDD in the ICU
(R2 = 0.1826, p = 0.038) (Fig. 4b).
Correlation between consumption of carbapenem and
resistance of A. baumannii to carbapenem
A. baumannii was the most common MDRO in our
study, and most A. baumannii are resistant to carba-
penem. Therefore, we calculated the numbers of patients
whose colonization or infection with A. baumannii were
resistant to carbapenem at the time of ICU admission
and discharge every month before and after the anti-
microbial management. We also calculated the total car-
bapenem consumption in our hospital and in the ICU
during the three-year study period. We analyzed the cor-
relation between the consumption of carbapenem and
the resistance of A. baumannii to carbapenem.
The proportion of patients colonized or infected with A.
baumannii resistant to carbapenem at the time of ICU ad-
mission and discharge is presented in Fig. 5. The carba-
penem consumption in our hospital and in the ICU
during the three-year period decreased from 10.1 to 5.7%
at the time of ICU admission and from 20.5 to 15.4% at
the time of ICU discharge after the intervention. However,
the DDD of carbapenem in the hospital and in the ICU
did not significantly change after the intervention (1.33 ±
0.33 vs. 1.26 ± 0.28, p = 0.446 and 18.2 ± 5.4 vs. 23.2 ± 7.7,
p = 0.573, respectively). There was no significant relation-
ship between the consumption of carbapenem in the
hospital and resistance of A. baumannii to carbapenem at
the time of ICU admission (R2 = 0.0436, p = 0.393)
(Fig. 5a). Similar results were found between the con-
sumption of carbapenem in the ICU and the resistance of
Fig. 2 Proportion of patient colonization of infection with MDRO at
the time of ICU admission and discharge decreased after antimicrobial
clinical application management
Table 3 Proportion of patients colonized or infected with MDRO before and after antimicrobial stewardship
Department All patients (978) Before management (433) After management (545) p value
All, n (%) 225 (23.01) 154 (35.57) 71 (13.03) <0.001
Emergency, n (%) 86 (23.76) 54 (40.91) 32 (17.68) <0.001
Surgery, n (%) 91 (19.24) 68 (33.17) 23 (8.58) <0.001
Neurosurgery, n (%) 11 (13.75) 5 (29.41) 6 (9.52) 0.035
Thoracic surgery, n (%) 12 (10.52) 11 (20.37) 1 (1.67) 0.001
General surgery, n (%) 35 (26.92) 28 (40.00) 7 (11.67) <0.001
Urology surgery, n (%) 10 (28.57) 8 (38.10) 2 (14.29) 0.252
Orthopedics, n (%) 8 (18.18) 8 (40.00) 0 (0) 0.001
Other, n (%) 13 (18.57) 6 (26.09) 7 (14.89) 0.258
Medicine, n (%) 50 (27.47) 34 (30.52) 16 (16.84) 0.033
Respiratory medicine, n (%) 10 (32.26) 8 (50.00) 2 (13.33) 0.054
Neurology, n (%) 13 (38.23) 8 (42.11) 5 (33.33) 0.728
Cardiology, n (%) 7 (15.22) 5 (21.73) 2 (8.70) 0.218
Other, n (%) 20 (25.00) 13 (35.14) 7 (16.28) 0.062
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A. baumannii to carbapenem at the time of ICU discharge
(R2 = 0.0798, p = 0.181) (Fig. 5b).
The incidence of HCAIs before and after antimicrobial
stewardship
During the intervention, we also monitored the inci-
dence of ventilator associated pneumonia (VAP), cath-
eter related blood stream infection (CRBSI) and catheter
associated urinary tract infection (CAUTI), which were
the most common of health-care-associated infections
(HCAIs) in our ICU. We found that the incidence of
VAP was significantly decreased after the intervention.
However, the incidence of CRBSI and CAUTI did not
change after the antimicrobial stewardship (Additional
file 2: Table S2).
Discussion
Infection with MDRO is frequently observed during
clinical treatment [15–17], especially in critically ill
patients [18]. Preventing infection with MDRO is very
important to our clinic workers. To the best of our
knowledge, this is the first study concerning the effect of
the antimicrobial stewardship program of Chinese MOH
on colonized or infected with MDRO in critically ill
patients. In the present study, we found that DDD in the
hospital and in most departments decreased signifi-
cantly after the implementation of the antimicrobial
stewardship.
Consequently, the MDRO isolation in critically ill pa-
tients correspondingly decreased when they admitted
into ICU. However, we found a low relationship between
DDD in the ICU and increased MDRO rate from ICU
admission to discharge. Moreover, we did not find a
positive relationship between DDD in the ICU and
MRDO at ICU or between the DDD of carbapenem and
carbapenem-resistant A. baumannii.
Antimicrobial stewardship can reduce the DDD in the
entire hospital and in the majority of the departments.
After the intervention, we found that the rational use of
antibiotics had improved. In the preventative use of anti-
biotics in clean operation, for example, the percentage
decreased from nearly 100 to 35%, which was in line
with previous data [19]. Consequently, the DDD was de-
creased significantly from 96 to 65 in our hospital and
was decreased in most departments (Table 2). Our
results confirmed the previous results in China [20].
However, our DDD is still higher than the standard
claimed by the policy. Therefore, we should conscien-
tiously execute this policy to improve antibiotic use.
Antimicrobial stewardship can help to decrease the
MDRO isolation in critically ill patients. Along with the
decrease in antimicrobial consumption in our study, the
proportion of colonization or infection with MDRO in
critically ill patients decreased significantly to 13%. Fur-
thermore, we found a good positive correlation between
antibiotic consumption and MDRO in our hospital (Fig. 3).
Previous studies demonstrated the association between
antimicrobial use and MDRO detection [2–4, 21]. Bassetti
et al. found a significant correlation between antibiotic
consumption and increased resistance for K. pneumonia
[21]. A recent study in China demonstrated that increased
consumption of carbapenem may contribute to the devel-
opment of resistance in A. baumannii to imipenem, mero-
penem, and other antimicrobials [4]. However, Most
previous studies were demonstrated that with the
increased consumption of antimicrobials, the MDRO in-
creased correspondingly [2–4, 21–23]. There was only the
some correlation between MDRO and antimicrobial con-
sumption. Whether the decrease antimicrobial consump-
tion could reduce the MDRO was not very clear.
Table 4 Microorganisms isolation at the time of ICU admission
and discharge
ICU admission ICU discharge
All microorganisms 1054 (100) 1040 (100)
Multidrug-resistant bacteriaa 273 (25.9) 369 (35.5)
Methicillin-resistant
Staphylococcus aureusb
75 (27.4) 74 (20.1)
Vancomycin-resistant
enterococcib
10 (3.6) 8 (2.2)
Pseudomonas aeruginosab 12 (4.4) 18 (4.9)
Acinetobacter baumanniib 83 (30.4) 150 (40.7)
Escherichia colib 24 (8.8) 27 (7.3)
Klebsiella oxytocab 15 (5.5) 24 (6.5)
Enterobacter cloacaeb 5 (1.8) 3 (0.5)
Proteus speciesb 1 (0.4) 4 (1.1)
Otherb 46 (16.8) 59 (16.0)
Non-multidrug-resistant
bacteriaa
781 (74.1) 671 (64.5)
Staphylococcus epidermidisc 375 (45.7) 307 (45.8)
Staphylococcus haemolyticusc 33 (4.2) 32 (4.8)
Methicillin-sensitive
Staphylococcus aureusc
49 (6.3) 51 (7.6)
Enterococcus speciesc 18 (2.6) 21 (3.1)
Pseudomonas aeruginosac 15 (1.9) 13 (1.9)
Acinetobacter baumanniic 10 (1.3) 11 (1.6)
Escherichia colic 26 (3.3) 20 (3.0)
Klebsiella oxytocac 100 (12.8) 84 (12.5)
Enterobacter cloacaec 13 (1.7) 12 (1.8)
Proteus speciesc 7 (0.9) 6 (0.9)
Othersc 140 (17.9) 111 (16.5)
Data were presented by counts and percentage
aPercentage equals the counts of the item divided by all microorganisms
bPercentage equals the counts of the item divided by multidrug-resistant bacteria
cPercentage equals the counts of the item divided by non-multidrug-resistant bacteria
ICU intensive care unit
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Interestingly, we found that the proportion of patients col-
onized or infected with MDRO decreased along with
reduced consumption of antibiotics.
In some departments, such as the thoracic surgery de-
partment, the DDD did not decrease; however, the
MDRO isolation rates in this department decreased sig-
nificantly in critically ill patients. Several reasons may
explain this decrease. First, DDD did not equal to
rational application of antimicrobials. Moreover, the
sample from such departments was small and could not
achieve significance. Finally, MDRO are easily transmit-
ted from patient to patient through hand contact with
doctors, nurses and hospital workers [22, 23]. Addition-
ally, critically ill patients were transferred several times
to different departments before being initially admitted
into the ICU. Therefore, the incidence of MDRO isolates
Fig. 3 A significant positive relationship between the proportion of critically ill patient colonization or infection with MDRO at the time of ICU
admission monthly and total antimicrobial consumption in our hospital monthly (R2 = 0.7858, p < 0.001)
Fig. 4 a There was no relationship between the DDD in the ICU and
the MDRO rate at the time of ICU discharge (R2 = 0.1085, p = 0.116);
b there was significant relationship between increased percentage
of MDRO rate from the time of ICU admission to discharge from the
ICU and DDD in the ICU (R2 = 0.2056, p = 0.038)
Fig. 5 a There was no significant relationship between carbapenem
consumption throughout the hospital and resistance of A. baumannii
to carbapenem at the time of ICU admission (R2 = 0.0436, p = 0.393).
b There was no significant relationship between carbapenem consumption
in the ICU and resistance of A. baumannii to carbapenem at the time of ICU
discharge (R2 = 0.0798, p=0.181)
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in patients from different departments and throughout
the hospital decreased, although DDD did not decrease.
Carbapenem-resistant A. baumannii is a serious prob-
lem in the clinic, especially in the ICU [24, 25]. Although
the DDD of carbapenem did not decrease in the entire
hospital and in the ICU, the carbapenem-resistant A.
baumannii isolates decreased both at the time of ICU ad-
mission and at ICU discharge. Moreover, we did not find
a good relationship between carbapenem consumption
and carbapenem-resistant A. baumannii. Because previ-
ous studies have examined whether carbapenem restric-
tion can reduce the rates of carbapenem-resistant A.
baumannii and have had inconsistent findings [4, 26],
further explorations are warranted to confirm these results.
Our study has several limitations. First, this study was
performed in a single center. Because drug resistance rates
vary among hospitals and units, the results may not be
representative and reproducible in other institutions.
However, in one hand, antibiotic overuse is common in
China [10], and antimicrobial stewardship can improve
the use of antibiotics. In another hand, the results of anti-
microbial consumption in our study was in line with
previous report [20]. Additionally, studies have demon-
strated that the rational use of antibiotics could prevent
antimicrobial resistance [27]. Therefore, we believe that
our study can benefit other hospitals.
Second, we did not analyze the individual risk factors
for colonization or infection with resistant microorgan-
isms. Factors that would affect the MDRO isolation, such
as hand hygiene, isolating the high-risk patients, and tak-
ing precautions, were not analyzed. However, during this
pre-post study period in our hospital, we had taken execu-
tive infection control measures. We found that the com-
pliance of hand hygiene did not significantly change in
our department. Therefore, we believe that the decrease of
DDD is an important factor for reducing the rate of
MDRO. We also plan to investigate and analyze the risk
factors concerning infection and MDRO.
Third, we did not screen the MDRO since rectal
swabs, and the proportion of undetected MDRO coloni-
zations could consequently be high. However, the policy
of screen was the same during the two periods, there-
fore, it will not be influence our results hugely.
Finally, our study did not address the issue of anti-
biotic use and resistance in the community. The con-
sumption of antimicrobials in agricultural industry may
also promote antibiotic resistance [28, 29]. However, the
MDRO isolation of patients who arrived from emer-
gency department also decreased from 40 to 18% and
may not affect our results.
Conclusion
The present study has demonstrated that the antibacterial
drug clinical application management established by
China’s Ministry of Public Health can improve the rational
use of antibiotics and reduce the antibiotic consumption.
Consequently, with the decrease of DDD in the hospital,
the proportion of colonization or infection with MDRO
correspondingly decreased. There was a significant posi-
tive relationship between the proportion of all critically ill
patients colonized or infected with MDRO at the time of
ICU admission and the DDD of the all hospital. However,
this relationship did not exist in the local department or
DDD of the individual medication.
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